首页> 外文期刊>Infection and Drug Resistance >The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae
【24h】

The β-lactamase inhibitor avibactam (NXL104) does not induce ampC β -lactamase in Enterobacter cloacae

机译:β-内酰胺酶抑制剂avibactam(NXL104)在阴沟肠杆菌中不诱导ampCβ-内酰胺酶

获取原文
           

摘要

Abstract: Induction of ampC β-lactamase expression can often compromise antibiotic treatment and is triggered by several β-lactams (such as cefoxitin and imipenem) and by the β-lactamase inhibitor clavulanic acid. The novel β-lactamase inhibitor avibactam (NXL104) is a potent inhibitor of both class A and class C enzymes. The potential of avibactam for induction of ampC expression in Enterobacter cloacae was investigated by ampC messenger ribonucleic acid quantitation. Cefoxitin and clavulanic acid were confirmed as ampC inducers, whereas avibactam was found to exert no effect on ampC expression. Thus, avibactam is unlikely to diminish the activity of any partner β-lactam antibiotic against AmpC-producing organisms.
机译:摘要:诱导ampCβ-内酰胺酶表达通常会损害抗生素治疗,并由几种β-内酰胺(例如头孢西丁和亚胺培南)和β-内酰胺酶抑制剂克拉维酸引发。新型的β-内酰胺酶抑制剂avibactam(NXL104)是A类和C类酶的有效抑制剂。通过ampC信使核糖核酸定量研究了avibactam诱导阴沟肠杆菌中ampC表达的潜力。确认头孢西丁和克拉维酸是ampC诱导剂,而阿巴巴坦对ampC表达没有影响。因此,avibactam不太可能降低任何伴侣β-内酰胺抗生素对产生AmpC的生物的活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号